David Dobbs
Contributing writer
The Transmitter
From this contributor
Remembering Mark Hallett, leader in transcranial magnetic stimulation
The long-time NINDS researcher, best known for studying movement disorders, has died at age 82.
Remembering Mark Hallett, leader in transcranial magnetic stimulation
The new history of autism, part III
For decades, two figures have dominated the history of autism studies. Today, newly excavated documents are calling into question the primacy of these men as founders of the field.
The new history of autism, part II
For decades, two figures have dominated the history of autism studies. Today, newly excavated documents are calling into question the primacy of these men as founders of the field.
The new history of autism, part I
For decades, two figures have dominated the history of autism studies. Today, newly excavated documents are calling into question the primacy of these men as founders of the field.
Rethinking regression in autism
The loss of abilities that besets some toddlers with autism is probably less sudden and more common than anyone thought.
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.